October 2017 in “Anesthesia and Pain Medicine” Repeated left stellate ganglion blocks may improve skin elasticity, water content, and hair follicle density on the treated side.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
April 2023 in “Journal of Investigative Dermatology” Injecting anti-herpes antibodies locally can prevent skin lesions and sweating problems caused by herpes simplex virus in mice.
7 citations
,
April 2017 in “Dermatologic surgery” Hyaluronic acid fillers and combination treatments significantly improve facial defects from autoimmune diseases and are well-tolerated.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
2 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The botanical treatment for hair loss shows promise, especially for children.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
11 citations
,
May 2010 in “Journal of Medicinal Chemistry” A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” Spironolactone and clascoterone are promising acne treatments with fewer side effects.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
17 citations
,
May 1995 in “Anatomy and Embryology” Injecting 6-OHDA in newborn mice delays hair growth and thins skin.
January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
A patient with Myotonic dystrophy type 1 had multiple tongue hemangiomas and was sensitive to anesthesia.
August 2023 in “Journal of Investigative Dermatology” Ganoderma lucidum extract and its component, ganoderic acid A, may effectively prevent hair loss.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2024 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” Mesotherapy can be beneficial but has risks if misused.
16 citations
,
November 2018 in “The journal of pain/Journal of pain” 14,15-EET may help reduce poststroke pain by affecting certain brain proteins.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
70 citations
,
January 2000 in “Drug Development Research” New butyric acid prodrugs show promise for cancer treatment, anemia management, and protecting hair from chemotherapy damage.